SAB Biotherapeutics
SABS
34 hedge funds and large institutions have $25.4M invested in SAB Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 35 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
5.58% less ownership
Funds ownership: 6.29% → 0.71% (-5.6%)
17% less funds holding
Funds holding: 41 → 34 (-7)
20% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 35
73% less capital invested
Capital invested by funds: $93.8M → $25.4M (-$68.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FPB
First PREMIER Bank
Sioux Falls,
South Dakota
|
+$7.81M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.41M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.75M |
| 4 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$1.86M |
| 5 |
IFAM
Institutional & Family Asset Management
Fort Collins,
Colorado
|
+$686K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$10.4M |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
-$6.55M |
| 3 |
KC
Kepos Capital
New York
|
-$6.3M |
| 4 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$5.5M |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$5.34M |
SABS Hedge Fund Activity: Q4 2021 in Review
34 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2021, worth a combined $25.4M — down 73% from $93.8M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of SABS and 28 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was First PREMIER Bank, opening a new position worth an estimated $7.81M. The largest seller was Karpus Investment Management, exiting entirely with an estimated $10.4M sold.
- 34 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2021, down from 41 in Q3 2021.
- Funds reported $25.4M of SAB Biotherapeutics stock for Q4 2021, down 73% quarter-over-quarter.
- 28 funds opened new SAB Biotherapeutics positions in Q4 2021 and 35 closed out, a net change of -7 holders.
- The largest SAB Biotherapeutics buyer in Q4 2021 was First PREMIER Bank, an estimated $7.81M added.
- The largest SAB Biotherapeutics seller in Q4 2021 was Karpus Investment Management, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2021.